TREATMENT OF CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH HYPERTENSION DISEASE: POTENTIAL THERAPEUTIC ROLE OF STATINES
| Autor: | S. G. Kanorsky, A. F. Sereda |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
verapamil
medicine.medical_specialty left ventricle Atorvastatin Diastole heart failure amlodipine law.invention Randomized controlled trial law Internal medicine Perindopril Medicine cardiovascular diseases Amlodipine Ejection fraction business.industry diastolic function atorvastatin General Medicine medicine.disease Brain natriuretic peptide preserved ejection fraction Heart failure Cardiology business medicine.drug |
| Zdroj: | Медицинский совет, Vol 0, Iss 20, Pp 26-31 (2018) |
| ISSN: | 2079-701X |
| DOI: | 10.21518/2079-701x-2017-20-26-31 |
| Popis: | The prospective randomized trial included 167 patients with functional class II-III of chronic heart failure (CHF) and a preserved left ventricular ejection fraction (LVEF) affected by hypertensive disease of stage III. In addition to antihypertensive therapy with perindopril and verapamil SR (n = 85) or amlodipine (n = 82), atorvastatin was prescribed, which was regularly taken by 50.6% and 48.8% of patients, respectively. After 12 months, patients in each treatment arm showed improvement in the clinical condition and quality of life, an increase in 6MWD (6-minute walk distance). The patients receiving atorvastatin demonstrated a significant reduction in the N-terminal prohormone of brain natriuretic peptide (NT-proBNP or BNPT) level, and a tendency to improve a diastolic LV function. Adding atorvastatin to the therapy of CHF with preserved LVEF may reasonably improve the prognosis of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|